AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04933227
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000 mg/m\^2/d will be administered orally (PO) twice daily (bid) on Days 1-14 during Cycles 1-4.
Trial: NCT05852717
Drug: GDP
RxNorm normalized name: GDPase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine Cisplatin Dexamethasone
Trial: NCT06034275
Drug: VIP943 (QW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIP943 will be administered by IV Infusion weekly
Trial: NCT06034275
Drug: VIP943 (BIW)
RxNorm normalized name: BREATHING CIRCUIT,BIWAZE COUGH,W/MOUTHPIECE,STANDARD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIP943 will be administered by IV Infusion bi-weekly
Trial: NCT05612607
Drug: Immunoglobulin replacement therapy (IGRT)
RxNorm normalized name: immunoglobulin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGRT discontinuation will be dependent on participant's SMB levels. If SMB cells are ≥ 2%, IGRT will be discontinued. If SMB cells are \< 2%, the patient will remain on IGRT and a maximum of 40 mL of blood will be drawn again in 3-6 months to reassess SMB levels and eligibility for IGRT discontinuation.
Trial: NCT05496738
Drug: PF-07264660 intravenous single ascending dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-07264660 will be administered intravenously in single ascending doses
Trial: NCT05496738
Drug: PF-07264660 subcutaneous multiple ascending dose
RxNorm normalized name: Influenza, high-dose, quadrivalent, PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-07264660 will be administered subcutaneously in multiple ascending doses
Trial: NCT05975125
Drug: Vitamin C 500 MG Oral Tablet
RxNorm normalized name: vitamin C 500 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: compare between Vitamin C with iron supplement and iron supplement alone in prevention of anemia in pregnancy.
Trial: NCT06604598
Drug: IBU-PCT-DEX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (Peinlos) 2x400 mg iv, Paracetamol (Bernofarm) 2x1 gr iv, dexamethasone (Phapros) 2x5 mg iv will be given with interval 8 hour, within the IBU-PCT-DEX intervention.
Trial: NCT06604598
Drug: IBU-PCT-placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (Peinlos) 2x400 mg iv, Paracetamol (Bernofarm) 2x1 gr iv, and 2xplacebo (normal saline alike dexamethasone) will be given with interval 8 hour, within the IBU-PCT-placebo intervention
Trial: NCT06604598
Drug: PCT-placebo-placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (Bernofarm) 2x1 gr iv, 2xplacebo (normal saline alike paracetamol), 2xplacebo (normal saline alike dexamethasone) will be given with interval 8 hour, within the PCT-placebo-placebo intervention.
Trial: NCT06253429
Drug: Thioctic Acid 333 MG Oral Capsule
RxNorm normalized name: thioctic acid 333 MG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant compound which serve as a cofactor for mitochondrial respiratory enzymes
Trial: NCT04802785
Drug: Dextrose Oral Tablet, Chewable
RxNorm normalized name: Dextrose Oral Tablet, Chewable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose 13.5 g per os
Trial: NCT04802785
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid 150 mg per os
Trial: NCT04802785
Drug: Probiotic Formula
RxNorm normalized name: Probiotic Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule per os.
Trial: NCT04802785
Drug: Melatonin 5 mg
RxNorm normalized name: melatonin 5 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin 5 mg per os.
Trial: NCT00002226
Drug: SU5416
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04784780
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with chronic constipation are administered placebo for 12 weeks
Trial: NCT05667402
Drug: TBF regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects receive TBF conditioning regimen (Thiotepa, Busulfan, Fludarabine) before allo-HSCT.
Trial: NCT05667402
Drug: modified BuCY2 regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects receive modified BuCY2 conditioning regimen (Busulfan, Cytarabine, ATG, Cyclophosphamide, CCNU) before allo-HSCT.
Trial: NCT05001555
Drug: Dexketoprofen/Vitamin B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule containing 25 mg of dexketoprofen / vitamin B (thiamine mononitrate 100 mg, Pyridoxine hydrochloride 50 mg, Cyanocobalamin 0.50 mg), orally, every 8 hours, for 7 days.
Trial: NCT05156125
Drug: VTX002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose A tablet administered orally once daily
Trial: NCT05156125
Drug: VTX002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose B Tablet administered orally once daily
Trial: NCT05156125
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Tablet for VTX002 administered orally once daily
Trial: NCT05848375
Drug: naropeine or chirocaine (Arthroscopic rotator cuff repair under LRA associated to GA)
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loco Regional Anesthesia is performed by injecting anesthetic (between 10 and 20 ml of naropeine or chirocaine) into the interscalene nerve block under ultrasound guidance associated to General Anesthesia performed by injection of diprivan and ultiva.
Trial: NCT05848375
Drug: naropeine or chirocaine (Arthroscopic rotator cuff repair under LRA)
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loco Regional Anesthesia is performed by injecting anesthetic (between 10 and 20 ml of naropeine or chirocaine) into the interscalene nerve block under ultrasound guidance
Trial: NCT06433011
Drug: r-tPA
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulse spray and infusion
Trial: NCT06362642
Drug: PC14586
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-in-class, oral, small molecule p53 reactivator that is selective for the TP53 Y220C mutation.
Trial: NCT04877691
Drug: Medi-546
RxNorm normalized name: Medi-Lyte
DrugBank: MEDI-547 (DB18360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will have IP administered or will self-administer IP under supervision by site staff at Week 0 and Week 1 and, for patients participating in the OLE period, at Week 52. For weekly doses coinciding with subsequent on-site visits, patients will also have IP administered or will self-administer IP under supervision by site staff, and in addition will receive a set of kits (including back-up kits) for at-home administration.
Trial: NCT04877691
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection in aPFS
Trial: NCT05198362
Drug: Tesomet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination
Trial: NCT04920292
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo tablet is made using the same non-active ingredients and matches the investigational tablet.
Trial: NCT05663593
Drug: HSK31858, tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose in single ascending dose: 5 mg
Trial: NCT05663593
Drug: Placebo, tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT04903509
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04903509
Drug: Saxenda®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saxenda®
Trial: NCT04903509
Drug: Paracetamol-ratiopharm®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol-ratiopharm®
Trial: NCT05726383
Drug: Iscador*P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iscador P given for 2 cycles with follow up imaging done every 2 cycles. If imaging is negative patient remains on study for 13 cycles. If new lesion is found, then patient is off study.
Trial: NCT05785767
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Q3W as IV co-infusion
Trial: NCT06618534
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A standard dose of azithromycin (500 mg) will be delivered by oral route.
Trial: NCT04938466
Drug: Long-Acting Growth Hormone (LAGH)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting growth hormone (LAGH) treatment
Trial: NCT05735496
Drug: TQB2102 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB2102 is an antibody-drug conjugate comprised of a humanised antibody against HER2, a enzyme-cleavable linker, and a topoisomerase I inhibitor payload.
Trial: NCT05379985
Drug: RMC-6236
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablets
Trial: NCT06023368
Drug: Num Vapocoolant Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spray applied around port prior to access
Trial: NCT06160440
Drug: SC1011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject in the SAD groups participated in 1 treatment period only and reside at the clinical research unit (CRU) from Day -1 (the day before dosing) to Day 7 (144 hours post dose).
Trial: NCT05574400
Drug: Caffeine citrate
RxNorm normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-dose caffeine citrate (1.5 mg/kg)
Trial: NCT05574400
Drug: Caffeine citrate
RxNorm normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose Caffeine citrate (3 mg/kg)
Trial: NCT04814433
Drug: Lidocaine Hydrochloride with Epinephrine
RxNorm normalized name: epinephrine / lidocaine hydrochloride Injection [Xylocaine with Epinephrine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lidocaine product is FDA approved as an amide local anesthetic in any indication for relief of pain associated with superficial minor surgery and as an adjunct for local infiltration anesthesia. It is frequently used as a standard local anesthetic for surgical procedures.~Each mL contains lidocaine hydrochloride and epinephrine, with 0.5 mg sodium metabisulfite as an antioxidant and 0.2 mg citric acid as a stabilizer.~Total of 5 mLs per open surgical study arm involving lidocaine hydrochloride and epinephrine will be given
Trial: NCT05257018
Drug: R-CDOP+intrathecal MTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CDOP+intrathecal MTX：~* Rituximab 375 mg / m\^2，D1~* Cyclophosphamide 750 mg / m\^2，D2~* Doxorubicin Hydrochloride Liposome Injection 35mg / m\^2，D2~* Vincristine 1.4mg/m\^2 (dose capped at 2 mg)，D2~* Prednisone 50 mg， bid D2-6~* Cycle1-5：Intrathecal MTX 12 mg + DXM 5 mg after chemotherapy （PK patients will be given 24 h after chemotherapy）
Trial: NCT05726630
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05431179
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After 16 weeks in the open-label Ibrutinib phase, participants will receive placebo administered by IV every 2 weeks for 3 administrations and then every 4 weeks thereafter.
Trial: NCT05052307
Drug: Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine
Trial: NCT05052307
Drug: ChAdOx1 nCoV-19 Covid-19 Vaccine
RxNorm normalized name: COVID-19 VACCINE ADENOVIRUS-26
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAdOx1 nCoV-19 Covid-19 Vaccine
Trial: NCT05052307
Drug: Ad26.COV2.S COVID-19 Vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad26.COV2.S COVID-19 Vaccine
Trial: NCT06300905
Drug: test product
RxNorm normalized name: Patch test product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: toothpaste containing 0.45% stannous fluoride
Trial: NCT06300905
Drug: Control product
RxNorm normalized name: Patch test control product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: toothpaste containing 0.76% sodium monofluorophosphate
Trial: NCT06140238
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline administration 15 minutes before start surgical operation
Trial: NCT05415397
Drug: Celecoxib 400mg
RxNorm normalized name: CELECOXIB 400MG CAP
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib add-on (400mg daily) add-on to treatment as usual (standard antidepressant treatment)
Trial: NCT05415397
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo add-on to treatment as usual (standard antidepressant treatment)
Trial: NCT06509074
Drug: Beta blocker
RxNorm normalized name: Beta blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pragmatic design. Any beta-blocker with alpha or NO activity may be used
Trial: NCT06499948
Drug: Treatment with Spironolactone followed by Dapagliflozin followed by their combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After titrating the renin-angiotensin-system inhibitor dose, patients will receive 25 mg of Spironolactone once daily for 4 weeks. Spironolactone will be stopped after 4 weeks. The first treatment period will be followed by 4 weeks of wash-out. After the first wash-out period, treatment with Dapagliflozin will be started. Patients will receive 10 mg of Dapagliflozin once daily for 4 weeks. Dapagliflozin will be stopped after 4 weeks. The second treatment period will be followed by 4 weeks of wash-out. After the second wash-out period, treatment with both Spironolactone 25 mg and Dapagliflozin will be started. Patients will receive 25 mg of Spironolactone once daily in combination with 10 mg of Dapagliflozin daily for a duration of 4 weeks. Spironolactone and Dapagliflozin will be stopped after 4 weeks. The third treatment period will be followed by 4 weeks of wash-out, after which the study will be finalized.
Trial: NCT06499948
Drug: Treatment with Dapagliflozin followed by Spironolactone followed by their combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After titrating the renin-angiotensin-system inhibitor dose, patients will receive 10 mg of Dapagliflozin once daily for 4 weeks. Dapagliflozin will be stopped after 4 weeks. The first treatment period will be followed by 4 weeks of wash-out. After the first wash-out period, treatment with Spironolactone will be started. Patients will receive 25 mg of Spironolactone once daily for 4 weeks. Spironolactone will be stopped after 4 weeks. The second treatment period will be followed by 4 weeks of wash-out. After the second wash-out period, treatment with both Spironolactone and Dapagliflozin will be started. Patients will receive 25 mg of Spironolactone once daily in combination with 10 mg of Dapagliflozin daily for a duration of 4 weeks. Spironolactone and Dapagliflozin will be stopped after 4 weeks. The third treatment period will be followed by 4 weeks of wash-out, after which the study will be finalized.
Trial: NCT04165486
Drug: ION464
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ION464 will be administered by IT injection.
Trial: NCT04165486
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ION464-matching placebo will be administered by IT injection.
Trial: NCT05994534
Drug: Cysteamine Bitartrate
RxNorm normalized name: Cysteamine Bitartrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose, tablets at current therapeutic dose
Trial: NCT06218784
Drug: Placebo Capsule (Part 1)
RxNorm normalized name: PLACEBO CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose: b.i.d for 7 days
Trial: NCT06218784
Drug: Placebo Capsule (Part 3)
RxNorm normalized name: PLACEBO CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose: b.i.d for 14 days
Trial: NCT04880889
Drug: Reference Pantogar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule
Trial: NCT04880889
Drug: BL3000 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule 500 mg
Trial: NCT04880889
Drug: Pantogar - Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule
Trial: NCT06092957
Drug: Full course of PD-1/PD-L1 blockades
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a) Camrelizumab 200mg, b) Toripalimab 240mg, or c) Adebrelimab 1200mg will be started on day 1 of induction chemotherapy and given every 3 weeks for up to 12 cycles, or until intolerable toxicity, or disease progression or withdrawal from the treatment.
Trial: NCT00000778
Drug: Pyridoxine hydrochloride
RxNorm normalized name: Pyridoxine Hydrochloride
DrugBank: Pyridoxine phosphate (DB02209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05157763
Drug: EscharEx 5% (EX-02 formulation)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EX-02 5% will be topically applied in a thick layer of 2-3 mm on the lesion surface for 8-12 hours including 5-10 mm margins and covered with an occlusive dressing. A new vial should be used for each application. Each patient will be treated with 7 applications.
Trial: NCT04817800
Drug: 140/100 μg Azelastine hydrochloride/Beclomethasone Dipropionate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It will be nasaly administered
Trial: NCT06372483
Drug: VMX-C001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VMX-C001 is human factor X engineered to be insensitive to factor Xa DOACs
Trial: NCT06372483
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VMX-C001 matched placebo
Trial: NCT06059001
Drug: OMO-103
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational Product: 35 mg/mL (4.5 mL/vial) concentrate for solution for infusion
Trial: NCT05738291
Drug: Placebo matching BI 1839100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching BI 1839100
Trial: NCT05738291
Drug: rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: rosuvastatin
Trial: NCT05432960
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline (0.9% Sodium Chloride solution)
Trial: NCT05712889
Drug: VIP236 (Q3W)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIP236 will be administered by IV infusion once every 3 weeks, for a 21-day cycle.
Trial: NCT05712889
Drug: VIP236 (Q2W)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIP236 will be administered by IV infusion once every 2 weeks, for a 28-day cycle.
Trial: NCT04650841
Drug: Placebo Cream with Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be informed that the spray is an effective pain and negative emotion reducing agent.
Trial: NCT04650841
Drug: Control Cream with Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be informed that the spray is saline.
Trial: NCT05810116
Drug: Levagen+
RxNorm normalized name: Levafen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose of 1-2 capsules (1 capsule containing 350mg Levagen+ equivalent to 300mg PEA)
Trial: NCT00240773
Drug: acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 grams daily for six months
Trial: NCT00240773
Drug: naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 750 mg daily for 12 months
Trial: NCT00240773
Drug: acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 grams daily for 12 months
Trial: NCT00240773
Drug: naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 750 mg daily for six months
Trial: NCT06359535
Drug: HSK21542
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study is an economic study and does not interfere with patients' medical treatment.
Trial: NCT06359535
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06345703
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NS-136 matching placebo
Trial: NCT06195111
Drug: Trifluridine/Tipiracil
RxNorm normalized name: TRIFLURIDINE/TIPIRACIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This a rospective observational study. There is no treatment allocation. Patients administered Trifluridine/Tipiracil by prescription
Trial: NCT04262427
Drug: Cyclophosphamide 50mg
RxNorm normalized name: CYCLOPHOSPHAMIDE 50MG TAB
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cytotoxic chemotherapy
Trial: NCT05516407
Drug: FEN164
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oil based. Full-spectrum medicinal cannabis plant extract with less than 0.08% THC.
Trial: NCT06220266
Drug: Phytoestrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: consume 1 capsule twice a day for 2 months which one capsule composed of dry weight 50 mg of Pueraria Mirifica 1or Pueraria Mirifica 2 or Pueraria Mirifica 3
Trial: NCT05417386
Drug: FOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of the drugs 5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan, and Leucovorin given by intravenous infusion
Trial: NCT05417386
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Part of the FOLFIRINOX drug combination, given by intravenous infusion
Trial: NCT05417386
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Taken Orally as part of Chemoradiation
Trial: NCT06500689
Drug: Allisartan Isoproxil/Sustained-Release Indapamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-blind period (Week 1\~Week 12): Allisartan Isoproxil/Sustained-Release Indapamide.~Open-label period (Week 13\~Week 52): Allisartan Isoproxil/Sustained-Release Indapamide.
Trial: NCT05704049
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Background Treatment; ATC code: N02BE01; Pharmaceutical form: As per local commercial product; Route of administration: Oral or intravenous (IV)